Fig. 2From: Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)Primary endpoint: Change in adjuvant treatment recommendation between the first and second tumor board (after knowledge of the ODX recurrence score)Back to article page